Juno Therapeutics, Inc. (NASDAQ:JUNO) has been given a consensus recommendation of “Hold” by the nineteen research firms that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $49.86.

A number of equities research analysts have weighed in on JUNO shares. BTIG Research raised Juno Therapeutics from a “sell” rating to a “neutral” rating in a report on Monday, August 28th. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 28th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $54.00 target price (up previously from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Barclays PLC started coverage on Juno Therapeutics in a report on Wednesday, September 6th. They issued an “overweight” rating and a $55.00 target price on the stock. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $59.00 target price on shares of Juno Therapeutics in a report on Tuesday, October 31st.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,869 shares of Juno Therapeutics stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $39.95, for a total transaction of $514,116.55. Following the completion of the transaction, the executive vice president now owns 50,289 shares in the company, valued at approximately $2,009,045.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $42.66, for a total value of $511,920.00. Following the transaction, the director now owns 783,536 shares of the company’s stock, valued at approximately $33,425,645.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 79,670 shares of company stock valued at $3,553,777. 15.26% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in JUNO. Vanguard Group Inc. raised its holdings in shares of Juno Therapeutics by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after purchasing an additional 131,864 shares during the period. Capital International Investors bought a new stake in shares of Juno Therapeutics in the 3rd quarter worth approximately $256,339,000. BlackRock Inc. raised its holdings in shares of Juno Therapeutics by 2.6% in the 2nd quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after purchasing an additional 110,503 shares during the period. State Street Corp raised its holdings in shares of Juno Therapeutics by 7.4% in the 2nd quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock worth $96,742,000 after purchasing an additional 222,754 shares during the period. Finally, Capital World Investors raised its holdings in shares of Juno Therapeutics by 13.8% in the 2nd quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock worth $72,483,000 after purchasing an additional 295,000 shares during the period. Institutional investors and hedge funds own 66.71% of the company’s stock.

Shares of Juno Therapeutics (NASDAQ:JUNO) opened at $58.64 on Friday. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $61.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The firm’s quarterly revenue was up 115.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.57) earnings per share. analysts anticipate that Juno Therapeutics will post -4.02 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/juno-therapeutics-inc-juno-receives-consensus-rating-of-hold-from-brokerages/1713027.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.